Yanru Wang
Clinical trials sponsored by Yanru Wang, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can engineered immune cells tame autoimmune disease? Results expected Dec 2026 (estimated)
- New CAR-T therapy aims to fight hard-to-treat blood cancers Results expected Jun 2027 (estimated)
- Off-the-Shelf cell therapy takes aim at tough blood cancers Results expected Jun 2027 (estimated)
-
New CAR-T therapy aims to fight hard-to-treat blood cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called RN1701 for people with B-cell lymphoma that has come back or not responded to standard therapy. RN1701 uses specially engineered immune cells from a donor to target and kill cancer cells. The main goals are to check safety and s…
Phase 1 • Sponsor: YANRU WANG • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Off-the-Shelf cell therapy takes aim at tough blood cancers
Disease control Not yet recruitingThis early study tests a new treatment for people with B-cell blood cancers that have come back or not responded to standard therapy. The treatment uses donor immune cells (CAR-T cells) designed to find and attack cancer cells. The main goal is to check if it's safe, with a small…
Phase 1 • Sponsor: YANRU WANG • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC